LAB vs LIN · rev $174.4M vs P/E 34, rev $33.99B
Standard Biotools Inc (LAB) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
LAB currently screens at market cap $317.1M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the LAB and LIN stock pages for the full models.
Not investment advice.